Muronomab-CD3, also known by its trade name Orthoclone OKT3, is historically significant as it was the first monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for use in humans in 1986, for the prevention of kidney transplant rejection. This groundbreaking development not only demonstrated the potential of mAbs in clinical practice but also set the foundation for future research and therapeutic strategies.
Development of Muronomab
Muronomab-CD3 is a mouse IgG2 developed via hybridoma technology, a method pioneered by Georges Köhler and César Milstein in 1975, which later earned them the Nobel Prize. The antibody was specifically designed to bind to the CD3 receptor on T cells, which plays a crucial role in the cellular immune response.
The primary action of muronomab is immunosuppression, achieved by binding to the epsilon unit of the CD3 complex on the surface of T cells. This binding leads to the modulation and eventual depletion of T cells, thereby preventing the cellular immune response responsible for organ rejection. The mechanism involves both the blocking of antigen recognition and the direct induction of T-cell apoptosis.1
Clinical Applications and Efficacy
Initially approved for preventing acute rejection in renal transplantation, muronomab was a cornerstone drug in transplant immunology. It showed remarkable efficacy in reducing the incidence of reversing acute renal, hepatic, cardiac and combined kidney-pancreas transplant rejection episodes, thus improving graft survival rates. However, its use was often limited by significant side effects, including cytokine release syndrome, which resulted from the massive T-cell activation and subsequent release of cytokines. These cytokines caused flu-like symptoms, fever, and in severe cases, could be life-threatening.2
Unfortunately, in 2010, muromonab was withdrawn from use due to the frequency of those severe adverse reactions and mild and transient serum enzyme elevations during therapy, although it was not linked to cases of clinically apparent liver injury. Since muromonab is a potent immunosuppressive agent, it could cause the reactivation of hepatitis B in susceptible patients.3
Impact and Legacy
The approval of muronomab not only validated the clinical utility of monoclonal antibodies but also encouraged the pharmaceutical industry to invest in this technology. Following muronomab, several other monoclonal antibodies have been developed and approved, targeting diseases like cancer, rheumatoid arthritis, and multiple sclerosis.
Strohl, W. R., & Strohl, L. M. (2012). Variable chain engineering – humanization and optimization approaches. Therapeutic Antibody Engineering, 111-595. https://doi.org/10.1533/9781908818096.111
Todd, P.A., Brogden, R.N. (1989). Muromonab CD3. Drugs 37, 871–899. https://doi.org/10.2165/00003495-198937060-00004
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. (2012). Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548590/
The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.
Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.
Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.
Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.